Emyria (ASX:EMD) - Managing Director, Dr Michael Winlo
Managing Director, Dr Michael Winlo
Source: Emyria
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Emyria (EMD) reports positive bioanalytical results of its ultra-pure CBD formulation
  • In a pre-clinical animal study, Emyria compared its ultra-pure cannabidiol formulation, the EMD-003 capsule, to the only registered CBD product in Australia and the US, Epidyolex oil
  • Results demonstrated that EMD-003 had a greater peak concentration and improved bioavailability compared to an equivalent dose of Epidyolex over a 24-hour period
  • Emyria is aiming to target registration of EMD-003 as a low-dose, over-the-counter CBD medicine with the TGA in 2022
  • Company shares are up 2.74 per cent, trading at 37.5 cents

Emyria (EMD) has reported positive bioanalytical results of its ultra-pure CBD formulation.

Emyria has been working with Altasciences to develop a proprietary CBD capsule, which is made of FDA-approved ingredients.

In a pre-clinical, head-to-head animal study, Emyria compared its ultra-pure cannabidiol formulation, the EMD-003 capsule, to the only registered CBD product in Australia and the US, Epidyolex oil.

Eight canine subjects were administered single doses of EMD-003, Epidyolex and two other test formulations. For each treatment, 12 blood samples were collected over 24 hours for each subject and analysed for CBD concentration.

Results demonstrated that EMD-003 had a greater peak concentration and improved bioavailability, compared to an equivalent dose of Epidyolex over a 24-hour period. Bioavailability is a measure of the amount of can be given in a lower dose to a patient to achieve the same outcome.

Emyria’s Managing Director, Dr. Michael Winlo said he was delighted to receive the positive bioanalysis results.

“We were eager to evaluate the bioavailability of our formulation compared to the only successfully registered and reimbursed CBD oil in the market to date, Epidyolex,” Dr Winlo explained.

“These animal study results suggest Emyria has developed a novel, high performing and cost-effective CBD capsule that can meet the strict registration requirements for product quality and purity with both the TGA in Australia and the FDA in the US.”

“These results also give us the confidence to launch additional cannabinoid registration programs with the TGA and FDA based on the underlying formulation approach.”

Emyria is aiming to target registration of EMD-003 as a low-dose, over-the-counter CBD medicine with the TGA in 2022.

Company shares were up 2.74 per cent, trading at 37.5 cents at 3:17 pm AEDT.

EMD by the numbers
More From The Market Herald

" Frugl (ASX:FGL) releases new grocery app update

Retail intelligence ecosystem Frugl (ASX: FGL) has released version 3.0 of Frugl Grocery, a free grocery…

" Vanadium Resources (ASX:VR8) increases stake in Steelpoortdrift Project

Vanadium Resources (A:VR8) increased its interest to 73.95 per cent in the Tier 1 Steelpoortdrift Vanadium…

" PNX Metals (ASX:PNX) aims to raise $4.6 million from entitlement offer

PNX Metals (ASX:PNX) is aiming to raise $4.6 million through a non-renounceable entitlement offer.
The Market Herald Video

" Beforepay (ASX:B4P) still in the red after Monday debut

Beforepay Group (ASX:B4P) still in the red after Monday debut